Nuclemed SRL
Nuclemed reported total assets of 53,689 € at the end of the 2025 financial year (annual accounts filed with the NBB on 27 Aug 2026).
The score of Nuclemed shows with a free account.
See the score- Summary? / 5
- Balance sheet strength
- Liquidity
- Repayment capacity
- Profitability
- Trajectory
- Compliance and register
- Position in its sectorvs peers
- Supplier creditat 30 d
- Borrowing capacityborrowable
- Valuationcentral
Visible once signed in: create your account, the 14-day Pro trial is free.
Key figures 2025
Change 2022 → 2025: Equity -77 % Total assets -13 %
Accounts of the company itself (not consolidated).
The full file covers 9 financial years; a free account shows 2. →Deterministic calculation on the filed accounts, no AI. Dispute the score or report an error
Nuclemed's annual accounts
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Net result | −18,346 € | ||||
| Equity | 8,739 € | ||||
| Cash | 35,430 € | ||||
| EBITDA | −14,608 € | ||||
| Total assets | 53,689 € |
Filed annual accounts
- Year ended 31 Dec 2025filed on 27 Aug 2026
- Year ended 31 Dec 2024filed on 28 Aug 2025
- Year ended 31 Dec 2023filed on 30 Aug 2024
- Year ended 31 Dec 2022filed on 28 Aug 2023
- Year ended 31 Dec 2021filed on 19 Jul 2022
Nuclemed's financial analysis
- Solvency16.3%sector median: 47.4%
- Current ratio
- Net margin
- ROE
- Financial debt / EBITDA
- Interest coverage
- Days sales outstanding (DSO)
Management and control of Nuclemed
Nuclemed's publications in the Belgian Gazette
Company number, VAT number and registered office
- Company number (CBE)
- 0435.002.834
- VAT number
- BE0435002834
- Peppol
- Registered · 0208:0435002834 · as of 10 Nov 2026
- Legal form
- SRL
- Incorporated
- 05 Aug 1988
- Registered office
- 8800 Roeselare
- Latest accounts
- 2025 · filed on 27 Aug 2026
- Activity
- Retail sale of medical and orthopaedic goods, except corrective glasses, lenses and sunglasses (NACE 47741)
Nuclemed (SRL) has been based in Roeselare since 1988, active in: retail sale of medical and orthopaedic goods, except corrective glasses, lenses and sunglasses. For 2025, it reports a net loss of 18,346 € and equity of 8,739 €; its revenue is not published. Its solvency stands at 16.3%, below the median of its sector (47.4%).
Companies similar to Nuclemed
Companies in the same business, of comparable size and area, outside its group.
- Arterix Retail sale of medical and orthopaedic goods Destelbergen · balance sheet 9,206 €
- Medico Retail sale of medical and orthopaedic goods Halle · balance sheet 52,839 €
- Auditoor Retail sale of medical and orthopaedic goods Buggenhout · balance sheet 52,161 €
- Life International Retail sale of medical and orthopaedic goods Schelle · balance sheet 51,768 €
- Cecosur Retail sale of medical and orthopaedic goods Jette · balance sheet 51,271 €
- Van Huiden Consultancy Retail sale of medical and orthopaedic goods Antwerp · balance sheet 50,967 €
- Audio Noord Retail sale of medical and orthopaedic goods Antwerp · balance sheet 56,984 €
- CircuitLife Europe Retail sale of medical and orthopaedic goods Steenokkerzeel · balance sheet 49,903 €
Frequently asked questions about Nuclemed
What is the revenue of Nuclemed?
Nuclemed files its accounts in a format where revenue is optional: it is not published for 2025.
What is the VAT number of Nuclemed?
In Belgium, the VAT number is the company number prefixed with BE: BE0435002834 for Nuclemed, if the company is VAT-registered. Its company number (CBE) is 0435.002.834.
Where is the registered office of Nuclemed?
According to the CBE register, the registered office of Nuclemed is in 8800 Roeselare.
What is the equity of Nuclemed?
At the close of the 2025 financial year, the equity of Nuclemed amounts to 8,739 €, a solvency of 16.3% of total assets.
Who manages Nuclemed?
The register lists 1 active mandates at Nuclemed. Names and roles are in the full file, with the deeds published in the Belgian Gazette.
The full file of Nuclemed
Directors and mandates, ownership network, Gazette deeds, ten years of accounts and ratios, Excel export, and Idonis's analysis in one question.
Open the full file →